14 results about "Nicotine Addiction" patented technology

The invention discloses application of parthenolide in preparation of a medicine for preventing and / or treating nicotine addiction, and belongs to the technical field of medicines. Research finds that different doses of parthenolide can significantly prevent formation of nicotine-induced mouse CPP and formation of nicotine forced foraging; different doses of parthenolide can also significantly improve the withdrawal symptom of nicotine without affecting the spontaneous movement ability of mice, and meanwhile, parthenolide can also prevent nicotine from reburning. Therefore, parthenolide can be used for preparing the medicine for preventing and / or treating nicotine addiction.

The invention discloses a composite probiotic preparation capable of improving sensitivity of low-dose nicotine and reducing usage amount of nicotine, and belongs to the crossing field of microbial technology and biological medicine. The compound probiotic preparation only improves the sensitivity of mice to low-concentration nicotine, does not improve the preference of the mice to the existing preference concentration, prevents aggravated smoking addiction, enables individuals to reach the satisfaction of smoking at ordinary times under the condition of low dosage of nicotine, and has the advantages of being simple in preparation process, low in cost and the like. The formulations may be used in combination with products in nicotine replacement therapy or alone. The compound probiotic preparation disclosed by the invention can be used for preparing functional foods, health-care products and medicines capable of improving the sensitivity of the low-concentration nicotine, and has a very wide application prospect.

The technical solution relates to smoking accessories, namely electronic cigarettes, and can be used as a device for vaping and helping to combat nicotine addiction. The technical solution described provides effective tools for reducing nicotine (aerosol, vapor) consumption and dependence by informing the user about the processes of nicotine (aerosol, vapor) consumption (encouraging mindful consumption), engaging awareness mechanisms during use of the device, and using restriction mechanisms that prevent unlimited consumption.

This invention discloses a nicotine-capturing smoking cessation drug composition based on molecular configuration matching, belonging to the field of smoking cessation drug technology. The drug consists of three organic functional molecules screened by molecular structure (each molecule has a specific configuration, see Figure 2) that self-assemble in a specific molar ratio under human physiological conditions to form a three-dimensional molecular cage. This molecular cage, through precise adaptation of its internal cavity configuration to the chair conformation of nicotine molecules (the configuration after binding is shown in Figure 3), specifically recognizes and encapsulates nicotine molecules, preventing them from crossing the blood-brain barrier and entering the brain by increasing molecular weight and enhancing polarity. This blocks the nicotine addiction reward pathway at its source, thereby eliminating nicotine addiction and physiological dependence. The drug of this invention only acts in the peripheral circulation, does not enter the central nervous system, does not act on brain nerve receptors, has no psychotropic side effects, and is non-addictive. The molecular cage-nicotine complex can be normally metabolized and completely excreted from the body. This invention, with precise molecular configuration matching as its core innovation, has a novel mechanism, extremely high safety, and gentle withdrawal, effectively reducing relapse rates. It is suitable for various nicotine-dependent populations and has extremely high clinical translational and patent protection value.

The invention provides a nicotine degrading enzyme mutant as well as a preparation method and application thereof. The invention provides a recombinant nicotine degrading enzyme mutant. On the basis of NicA2 with an amino acid sequence as shown in SEQ ID NO: 1, mutation is carried out at any one of the following positions: the 48th position, the 379th position, the 189th position, the 208th position, the 234th position, the 274th position, the 317th position, the 369th position, the 370th position, the 362th position, the 396th position, the 462th position and the 479th position. Compared with a wild type nicotine degrading enzyme, the mutant has the advantages that the nicotine degrading activity is obviously improved, and the mutant has higher application potential in the aspects of further preparing a medicine for treating nicotine addiction or nicotine poisoning and improving the nicotine degrading activity and stability.

Salts of cytisine have been prepared and incorporated in stable pharmaceutical compositions, including compositions comprising lactose. The salts are prepared by adding acid stock solutions to solutions of cytisine with heating, followed by cooling to ambient temperature. The salts and compositions are indicated in the treatment of nicotine addiction.

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH regulator selected from the group consisting of inorganic acids, inorganic buffers, and salts of inorganic acids, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention also relates to the liquid pharmaceutical composition for use in the treatment of tobacco addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco addiction and other forms of nicotine addiction.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

The present application discloses an artificial enzyme, which is prepared based on sequence modification of a natural enzyme having the activity of catalyzing the reaction of converting compound I (nicotine) into compound II (N-methyl-4-hydroxy-3-methylnicotinamide) shown as follows, and compound II (N-methyl-4-hydroxy-3-methylnicotinamide) can spontaneously hydrate to generate compound III (pseudo-oxidized nicotine), or the natural enzyme is nicotine dehydrogenase; the modification includes replacing at least one of the amino acids that hinder the release of the product with an amino acid with a smaller side chain. The artificial enzyme has a higher catalytic rate on the substrate than the natural enzyme, and is very promising in the preparation of drugs for treating nicotine addiction.

The subject of the application is a dietary food in the form of a functional powder for reducing nicotine craving, which is characterized in that it contains L-theanine in an amount of 2% to 6% of the total weight of the powder, as an ingredient supporting stress reduction and alleviating nicotine withdrawal symptoms, L-tyrosine in an amount of 5% to 10% of the total weight of the powder, supporting mood stabilization by increasing dopamine levels, kudzu extract in an amount of 1% to 4% of the total weight of the powder, which acts on reducing compulsive behaviors associated with nicotine addiction, Glucomannan in an amount of 10% to 20% of the total weight of the powder, promoting the feeling of satiety and regulating eating habits during the withdrawal period, carriers and excipients, such as maltodextrin and microcrystalline cellulose, in an amount of 60% to 80% of the total weight of the powder, ensuring form stability and ease of use.The preparation is intended to reduce nicotine cravings and support emotional balance in people addicted to tobacco products, especially during nicotine withdrawal.

According to the invention, the original traditional Chinese medicine preparation compound 511 for resisting morphine addiction is subjected to medicine taste addition and subtraction to form a new compound 511, and the medicine effect of resisting nicotine addiction is explored. A new compound 511 is formed on the basis of mechanism overlapping between opioid drugs and nicotine in a midbrain marginal dopaminergic system and in combination with experimental results of an earlier-stage research group, and the new compound 511 is guessed to be possibly capable of intervening in nicotine addiction. The novel compound 511 is safe in medication, can effectively intervene in formation of nicotine addiction, and also can remarkably inhibit decline of spontaneous movement of mice caused by stopping administration after nicotine addiction. Meanwhile, pathological injuries of liver, heart, spleen, lung, kidney and ileum organs caused by nicotine addiction dosage can be improved. In addition, the composition medicines of the compound are simpler, the curative effect is definite, the price is moderate, the economic burden of smoking cessation patients can be reduced, and the compound has a very good commercial prospect.

This invention provides smoking cessation support methods and systems to help smokers quit. [Solution] A method for supporting smoking cessation that clarifies the structure of nicotine addiction that hinders the achievement of smoking cessation into three elements: physical dependence, psychological dependence, and conditioned reflexes, and implements smoking cessation support in this order, comprising: a first step of presenting first information; a first determination step of determining whether the physical dependence has been overcome after a first predetermined period has elapsed since the presentation of the first information, and if the physical dependence has been overcome, proceeding to a second smoking cessation support for the psychological dependence; a second step of presenting second information; a second determination step of determining whether the psychological dependence has been overcome after a second predetermined period has elapsed since the presentation of the second information, and if the psychological dependence has been overcome, proceeding to a third smoking cessation support for the conditioned reflexes; and a third step of presenting third information.

The present disclosure relates to a chemical compound having the general formula (I):wherein R1 is a phenyl group and R2 is a meta-substituted phenyl group; and RTA is a substituted or unsubstituted thiazole ring. The disclosure also relates to said compound according to formula (I), in particular in its diastereomerically pure or enriched form, for use in therapy, in particular for treating and / or preventing age-related cognitive decline. Further, the disclosure relates to said compound according to formula (I) for use in improving cognitive functions, in particular for use in improving the spatial learning capabilities in human individuals. And, disclosure also relates to said compound according to formula (I) for use in the treatment and / or prevention of alcohol addiction, nicotine addiction and / or drug addiction, in particular cocaine and / or metamphetamine addiction.